title: Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas.
abstract: BACKGROUND
  To investigate the malignancy and differentiation of intraductal papillary-mucinous tumors (IPMTs) and mucinous cystic tumors (MCTs) of the pancreas, clinicopathologic characteristics and immunohistochemical features were analyzed.
  
  
  METHODS
  The clinicopathologic characteristics and immunohistochemical features of 24 patients with IPMT and 8 with MCT who underwent pancreatic resections at our hospital were examined. Immunohistochemical features analyzed included expression of p53 protein, proliferating cell nuclear antigen, integrins, interleukin-1 receptor type I, and hormone-associated receptors, and the factors correlated with malignancy were identified by multiple logistic regression.
  
  
  RESULTS
  Among the IPMTs, there were 16 intraductal papillary adenomas, 5 intraductal papillary adenocarcinomas, and 3 moderate dysplasias. Among the MCTs, there were 6 mucinous cyst adenomas and 2 mucinous cyst adenocarcinomas. Multivariate analysis revealed that of the clinicopathologic characteristics, only the presence of mural nodules (odds ratio (OR) 7.12, P = 0.044) was independently correlated with the malignancy of IPMTs, and that of the immunohistochemical features, only alpha integrin subunit expression was independently correlated with malignancy of pancreatic mucinous tumors (OR 15.6, P = 0.036), especially IPMTs (OR 35.7, P = 0.012).
  
  
  CONCLUSIONS
  These results indicate that alpha-containing integrin expression can be a significant marker of malignancy in pancreatic mucinous tumors.
authors.affiliation: Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Science, Nagoya 467-8601, Japan. cb8h-swi@asahi-net.or.jp
authors.forename: H
authors.initials: H
authors.lastname: Sawai
authors.forename: Y
authors.initials: Y
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Funahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuo
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Manabe
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000737:chemistry* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D021441:Carcinoma, Pancreatic Ductal / Q000737:chemistry* / Q000473:pathology; D002291:Carcinoma, Papillary / Q000737:chemistry* / Q000473:pathology; D018291:Cystadenoma, Mucinous / Q000737:chemistry* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D039081:Integrin alpha5beta1 / Q000032:analysis; D039503:Integrin alpha6 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000737:chemistry* / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis; D017472:Receptors, Interleukin-1 / Q000032:analysis; D053573:Receptors, Interleukin-1 Type I; D011980:Receptors, Progesterone / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D039081:Integrin alpha5beta1; D039503:Integrin alpha6; D011960:Receptors, Estrogen; D017472:Receptors, Interleukin-1; D053573:Receptors, Interleukin-1 Type I; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53